{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T19:12:46Z","timestamp":1789240366002,"version":"build-2803163510"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,1,30]],"date-time":"2021-01-30T00:00:00Z","timestamp":1611964800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,30]],"date-time":"2021-01-30T00:00:00Z","timestamp":1611964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s00415-021-10414-y","type":"journal-article","created":{"date-parts":[[2021,1,30]],"date-time":"2021-01-30T11:02:52Z","timestamp":1612004572000},"page":"2458-2465","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Immune checkpoint inhibitors for progressive multifocal leukoencephalopathy: a new gold standard?"],"prefix":"10.1007","volume":"268","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7767-755X","authenticated-orcid":false,"given":"Damien","family":"Roos-Weil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Am\u00e9lie","family":"Guihot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madalina","family":"Uzunov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Bellanger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Eymard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Saadoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Houillier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Idbaih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Demeret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Deback","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Leblond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Galanaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Shor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Pourcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,30]]},"reference":[{"key":"10414_CR1","doi-asserted-by":"publisher","first-page":"ofz024","DOI":"10.1093\/ofid\/ofz024","volume":"6","author":"M Kartau","year":"2019","unstructured":"Kartau M, Verkkoniemi-Ahola A, Paetau A et al (2019) The incidence and predisposing factors of John Cunningham virus-induced progressive multifocal leukoencephalopathy in Southern Finland: a population-based study. Open Forum Infect Dis 6:ofz024","journal-title":"Open Forum Infect Dis"},{"key":"10414_CR2","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1056\/NEJMoa1815039","volume":"380","author":"I Cortese","year":"2019","unstructured":"Cortese I, Muranski P, Enose-Akahata Y et al (2019) Pembrolizumab treatment for progressive multifocal leukoencephalopathy. N Engl J Med 380:1597\u20131605","journal-title":"N Engl J Med"},{"key":"10414_CR3","doi-asserted-by":"publisher","first-page":"e82","DOI":"10.1111\/bjh.16349","volume":"188","author":"M Uzunov","year":"2020","unstructured":"Uzunov M, Demeret S, Nguyen-Quoc S et al (2020) Postallogeneic transplantation progressive multifocal leukoencephalopathy successfully treated by nivolumab. Br J Haematol 188:e82\u2013e84","journal-title":"Br J Haematol"},{"key":"10414_CR4","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1056\/NEJMc1816198","volume":"380","author":"O Walter","year":"2019","unstructured":"Walter O, Treiner E, Bonneville F et al (2019) Treatment of progressive multifocal leukoencephalopathy with nivolumab. N Engl J Med 380:1674\u20131676","journal-title":"N Engl J Med"},{"key":"10414_CR5","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/nature04444","volume":"439","author":"DL Barber","year":"2006","unstructured":"Barber DL, Wherry EJ, Masopust D et al (2006) Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439:682\u2013687","journal-title":"Nature"},{"key":"10414_CR6","doi-asserted-by":"publisher","first-page":"e628","DOI":"10.1212\/NXI.0000000000000628","volume":"6","author":"C Kupper","year":"2019","unstructured":"Kupper C, Heinrich J, Kamm K, Bucklein V, Rothenfusser S, Straube A (2019) Pembrolizumab for progressive multifocal leukoencephalopathy due to primary immunodeficiency. Neurol Neuroimmunol Neuroinflamm 6:e628","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10414_CR7","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.3201\/eid2511.190705","volume":"25","author":"C Medrano","year":"2019","unstructured":"Medrano C, Vergez F, Mengelle C, Faguer S, Kamar N, Del Bello A (2019) Effectiveness of immune checkpoint inhibitors in transplant recipients with progressive multifocal leukoencephalopathy. Emerg Infect Dis 25:2145\u20132147","journal-title":"Emerg Infect Dis"},{"key":"10414_CR8","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1212\/WNL.0b013e31828c2fa1","volume":"80","author":"JR Berger","year":"2013","unstructured":"Berger JR, Aksamit AJ, Clifford DB et al (2013) PML diagnostic criteria: consensus statement from the AAN neuroinfectious disease section. Neurology 80:1430\u20131438","journal-title":"Neurology"},{"key":"10414_CR9","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1080\/10428194.2018.1474523","volume":"60","author":"D Adrianzen Herrera","year":"2019","unstructured":"Adrianzen Herrera D, Ayyappan S, Jasra S et al (2019) Characteristics and outcomes of progressive multifocal leukoencephalopathy in hematologic malignancies and stem cell transplant\u2014a case series. Leuk Lymphoma 60:395\u2013401","journal-title":"Leuk Lymphoma"},{"key":"10414_CR10","doi-asserted-by":"publisher","first-page":"4834","DOI":"10.1182\/blood-2008-10-186999","volume":"113","author":"KR Carson","year":"2009","unstructured":"Carson KR, Evens AM, Richey EA et al (2009) Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the research on adverse drug events and reports project. Blood 113:4834\u20134840","journal-title":"Blood"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-021-10414-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-021-10414-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-021-10414-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T15:11:41Z","timestamp":1624288301000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-021-10414-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,30]]},"references-count":10,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["10414"],"URL":"https:\/\/doi.org\/10.1007\/s00415-021-10414-y","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,30]]},"assertion":[{"value":"13 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"No conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}